The BRECISE project is set to hold its first face-to-face kick-off meeting in Madrid on March

20–21, 2025. This event will bring together project partners to advance key objectives and foster

collaboration in biomarker research and personalised medicine.

Why Madrid?

The meeting is strategically scheduled alongside the European Association of Urology (EAU)

Congress, one of the largest gatherings of urology experts. The congress provides an ideal

setting to discuss precision medicine, biomarker research, and innovative diagnostic

integration—core areas of focus for BRECISE.

Advancing Work Packages and Use Cases:

This two-day meeting marks a significant milestone in the project, offering an opportunity to

align strategies and accelerate progress.

The agenda will include:

• March 20 – Presentation of Work Packages (WPs), setting objectives, and refining

collaborative approaches.

• March 21 – Dedicated Use Case Meetings to explore real-world applications and define next

steps for three selected use cases.

Strengthening Collaboration in Personalised Medicine:

BRECISE is committed to advancing biomarker-based diagnostics and personalised treatment

strategies. By bringing together researchers, clinicians, policymakers, and patient

representatives, the project aims to bridge the gap between scientific innovation and practical

implementation in healthcare systems across Europe.

This meeting will play a crucial role in fostering collaboration among partners, ensuring that

BRECISE delivers meaningful progress in precision medicine. We look forward to productive

discussions and impactful outcomes that will shape the future of biomarker-driven healthcare.